{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:21:17Z","timestamp":1793406077731,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jconrel.2024.01.012","type":"journal-article","created":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:11:41Z","timestamp":1705191101000},"page":"567-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer"],"prefix":"10.1016","volume":"366","author":[{"given":"Emmanuel","family":"Douez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Allard-Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im\u00e8ne Ait Mohamed","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Jolivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Boursin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Maisonial-Besset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Chezal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Letast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Auvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Denevault-Sabourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.01.012_bb0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review)","volume":"54","author":"Schirrmacher","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1039882","article-title":"Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis","volume":"12","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0015","series-title":"Success. Drug Discov","first-page":"55","article-title":"Antibody\u2013drug conjugates: empowering antibodies for the fight against cancer","author":"Denevault-Sabourin","year":"2019"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ph13090245","article-title":"Antibody\u2013drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100074","article-title":"The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer","volume":"6","author":"Delgado","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0030","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/pro.2666","article-title":"Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate","volume":"24","author":"Marcoux","year":"2015","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0040","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.22.02447","article-title":"US Food and Drug Administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer","volume":"41","author":"Narayan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0045","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2022","journal-title":"Cancers."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","article-title":"Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody\u2013drug conjugates","volume":"32","author":"Khera","year":"2018","journal-title":"BioDrugs."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0065","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/17460441.2021.1858050","article-title":"Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy","volume":"16","author":"Deonarain","year":"2021","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","article-title":"Influence of molecular size on tissue distribution of antibody fragments","volume":"8","author":"Li","year":"2016","journal-title":"MAbs."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ddtec.2018.09.006","article-title":"Miniaturised \u2018antibody\u2019-drug conjugates for solid tumours?","volume":"30","author":"Deonarain","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.10662","article-title":"Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin","volume":"102","author":"Borsi","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0085","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/0008-5472.CAN-13-2990","article-title":"Curative properties of noninternalizing antibody\u2013drug conjugates based on maytansinoids","volume":"74","author":"Perrino","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0090","first-page":"3055","article-title":"Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts","volume":"56","author":"Hu","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0095","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/1078-0432.CCR-03-0576","article-title":"Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody Fragment (cT84.66 Minibody) in patients with colorectal cancer","volume":"10","author":"Wong","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0100","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1073\/pnas.1316922111","article-title":"Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo","volume":"111","author":"Tavar\u00e9","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/protein\/gzh040","article-title":"Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting","volume":"17","author":"Olafsen","year":"2004","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3390\/ijms24021239","article-title":"Minibody-based and scFv-based antibody fragment-drug conjugates selectively eliminate GD2-positive tumor cells","volume":"24","author":"Kalinovsky","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0115","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","article-title":"Protease-cleavable linkers modulate the anticancer activity of noninternalizing antibody\u2013drug conjugates","volume":"28","author":"Dal Corso","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0120","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acs.bioconjchem.8b00668","article-title":"Site-specific conjugation of Auristatins onto engineered scFv using second generation Maleimide to target HER2-positive breast cancer in vitro","volume":"29","author":"Aubrey","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0125","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C7OB02780J","article-title":"Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody\u2013drug conjugates","volume":"16","author":"Bryden","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114063","article-title":"Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate","volume":"229","author":"Mohamed Amar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0135","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0145","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody\u2013drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2017.02.027","article-title":"Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates","volume":"253","author":"Pabst","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody\u2013drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/bc1002746","article-title":"Production of a PEGylated Fab\u2019 of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination","volume":"22","author":"Pepinsky","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0170","series-title":"Antib. Methods Protoc","first-page":"233","article-title":"PEGylation of antibody fragments for half-life extension","author":"Jev\u0161evar","year":"2012"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114932","article-title":"Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation","volume":"392","author":"Simmons","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0180","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/antib10020020","article-title":"Clinical pharmacology of antibody-drug conjugates","volume":"10","author":"Mahmood","year":"2021","journal-title":"Antibodies."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0190","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.4155\/bio-2018-0259","article-title":"Immunogenicity of antibody\u2013drug conjugates: observations across 8 molecules in 11 clinical trials","volume":"11","author":"Carrasco-Triguero","year":"2019","journal-title":"Bioanalysis."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0195","doi-asserted-by":"crossref","first-page":"32110","DOI":"10.1021\/acsami.3c02762","article-title":"Cleavable-branched polymer-modified liposomes reduce accelerated blood clearance and enhance photothermal therapy","volume":"15","author":"Sui","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0200","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0205","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid\u2013valine\u2013citrulline linkers ensure stability and efficacy of antibody\u2013drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0210","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0215","author":"Loibl","year":"2023"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0220","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2020","volume":"0","author":"Loibl","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00477-z","article-title":"Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE","volume":"8","author":"Loibl","year":"2022","journal-title":"Npj Breast Cancer."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0230","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0235","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2\u2013positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/molecules28010075","article-title":"Synthesis and in vitro comparison of DOTA, NODAGA and 15-5 macrocycles as chelators for the 64Cu-labelling of immunoconjugates","volume":"28","author":"Maisonial-Besset","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0250","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/pharmaceutics14081524","article-title":"Intra-domain cysteines (IDC), a new strategy for the development of original antibody fragment\u2013drug conjugates (FDCs)","volume":"14","author":"Jolivet","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.01.012_bb0255","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molimm.2015.04.001","article-title":"In vivo imaging with antibodies and engineered fragments","volume":"67","author":"Freise","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0260","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0265","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/19420862.2015.1116657","article-title":"A method to confer protein L binding ability to any antibody fragment","volume":"8","author":"Lakhrif","year":"2016","journal-title":"MAbs."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0270","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/ph14030247","article-title":"Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform","volume":"14","author":"Conilh","year":"2021","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0275","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody\u2013cytotoxic drug conjugate","volume":"68","author":"Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0280","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1038\/s41598-021-93972-5","article-title":"PE38-based gene therapy of HER2-positive breast cancer stem cells via VHH-redirected polyamidoamine dendrimers","volume":"11","author":"Moradian","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0285","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/antib7010010","article-title":"Factors affecting the pharmacology of antibody\u2013drug conjugates","volume":"7","author":"Lucas","year":"2018","journal-title":"Antibodies."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0290","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug\u2013antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody\u2013maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0295","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/bc400439x","article-title":"Auristatin antibody drug conjugate physical instability and the role of drug payload","volume":"25","author":"Adem","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0300","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-08-0388","article-title":"Anti-CD30 diabody-drug conjugates with potent antitumor activity","volume":"7","author":"Kim","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0305","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-15-0480","article-title":"Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody\u2013drug conjugates","volume":"14","author":"G\u00e9bleux","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.01.012_bb0310","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody\u2013drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"G\u00e9bleux","year":"2017","journal-title":"Int. J. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T21:33:09Z","timestamp":1738099989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":62,"alternative-id":["S0168365924000166"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}